Results: 555

Adenocarcinomas do estômago relacionados com o vírus de Epstein-Barr: estudo dos aspectos clínico-patológicos e a relação com o infiltrado linfocitário com ênfase na expressão de PD-L1

O adenocarcinoma gástrico associado ao vírus Epstein-Barr (EBV) corresponde a cerca de 10% dos carcinomas gástricos, ocorre mais frequentemente em pacientes mais jovens e acomete preferencialmente a porção proximal do estômago. São tumores que com maior frequência exibem um crescimento sólido, a...

Effect of ethyl acetate extract of usnea longissima on esophagogastric adenocarcinoma in rats

Acta cir. bras; 34 (3), 2019
Abstract Purpose: To investigate the effects of the EtOAc extract of U. longissima which is uninvestigated previously on esophagogastric cancer induced in rats with N-methyl-N-nitro-N-nitrosoguanidin (MNNG). Methods: The anticancer activity of EtOAc extract of U. longissima was examined in the esopha...

MicroRNA-383-5p inhibits the progression of gastric carcinoma via targeting HDAC9 expression

Braz. j. med. biol. res; 52 (8), 2019
MicroRNAs (miRNAs), as post-transcriptional regulators, have been reported to be involved in the initiation and progression of various types of cancer, including gastric cancer (GC). The present study aimed to investigate the role of miR-383-5p in gastric carcinogenesis. Cell viability was analyzed using...

Kaempferol suppresses human gastric cancer SNU-216 cell proliferation, promotes cell autophagy, but has no influence on cell apoptosis

Braz. j. med. biol. res; 52 (2), 2019
Gastric cancer remains a serious threat to human health worldwide. Kaempferol is a plant-derived flavonoid compound with a wide range of pharmacological activities. This study aimed to investigate the effects of kaempferol on gastric cancer SNU-216 cell proliferation, apoptosis, and autophagy, as well as...

FGFR1 is an independent prognostic factor and can be regulated by miR-497 in gastric cancer progression

Braz. j. med. biol. res; 52 (1), 2019
Fibroblast growth factor receptor 1 (FGFR1) has been reported in gastric cancer to be a prognostic factor. However, miR-497-targeted FGFR1 has not been explored in the carcinogenesis of gastric cancer. The present study intended to revalidate the prognostic significance of FGFR1 in patients with gastric ...

Análisis retrospectivo de pacientes con cáncer gástrico localmente avanzado o metastásico en Argentina

Medwave; 19 (8), 2019
OBJETIVO Describir las características clínicas, los patrones de tratamiento y los costos asociados en pacientes con cáncer gástrico localmente avanzado o metastásico en Argentina, en los sectores público y privado. MÉTODOS Una cohorte histórica de pacientes que recibieron tratamiento de quimiote...

Protein expression profiles and clinicopathologic characteristics associate with gastric cancer survival

Biol. Res; 52 (), 2019
BACKGROUND: Prognosis remains one of most crucial determinants of gastric cancer (GC) treatment, but current methods do not predict prognosis accurately. Identification of additional biomarkers is urgently required to identify patients at risk of poor prognoses. METHODS: Tissue microarrays were used to m...

ErbB1 and ErbB3 co-over expression as a prognostic factor in gastric cancer

Biol. Res; 52 (), 2019
BACKGROUND: Epidermal growth factor receptor family members such as ErbB1 and ErbB3 are involved in tumor progression and metastasis. Although, there are various reports about the prognostic value of EGFR members separately in gastric cancer, there is not any report about the probable correlation between...

The ERBB2 gene polymorphisms rs2643194, rs2934971, and rs1058808 are associated with increased risk of gastric cancer

Braz. j. med. biol. res; 52 (5), 2019
Gastric cancer (GC) is the third most lethal type of cancer worldwide. Single nucleotide polymorphisms (SNPs) in regulatory sites or coding regions can modify the expression of genes involved in gastric carcinogenesis, as ERBB2, which encodes for the tyrosine-kinase receptor HER-2. The aim of this work w...

Impact of enhanced recovery after surgery on postoperative rehabilitation, inflammation, and immunity in gastric carcinoma patients: a randomized clinical trial

Braz. j. med. biol. res; 52 (5), 2019
We determined the effects of enhanced recovery after surgery (ERAS) in patients undergoing radical surgery for gastric carcinoma. Sixty patients undergoing radical gastrectomy for gastric carcinoma in Lishui Hospital between March and October 2016 were randomized to receive either ERAS (30 patients) or c...